

## PATENT COOPERATION TREATY

## PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>N.88110A TAC</b>	<b>FOR FURTHER ACTION</b> see Form PCT/ISA/220 as well as, where applicable, item 5 below.	
International application No. <b>PCT/GB2004/001663</b>	International filing date (day/month/year) <b>16/04/2004</b>	(Earliest) Priority Date (day/month/year) <b>16/04/2003</b>
Applicant  <b>MARGETTS, George</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 7 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

**1. Basis of the report**

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ The international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. ☐ With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, see Box No. I.

2. ☒ **Certain claims were found unsearchable** (See Box II).

3. ☐ **Unity of invention is lacking** (see Box III).

**4. With regard to the title,**

☐ the text is approved as submitted by the applicant.

☒ the text has been established by this Authority to read as follows:

**USE OF STEROID DERIVATIVES FOR THE TREATMENT OF ANGIOTENSIN II RELATED DISEASES  
E.G. CARDIOVASCULAR AND PROLIFERATIVE DISORDERS**

**5. With regard to the abstract,**

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

**6. With regards to the drawings,**

- a. the figure of the **drawings** to be published with the abstract is Figure No. \_\_\_\_\_

☐ as suggested by the applicant.

☐ as selected by this Authority, because the applicant failed to suggest a figure.

☐ as selected by this Authority, because this figure better characterizes the invention.

- b. ☒ none of the figures is to be published with the abstract.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB2004/001663

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/565 A61K31/568 A61P9/00 A61P35/00 A61P11/06  
A61P13/12

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, PAJ, WPI Data, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2003/050291 A1 (ARAD YADON) 13 March 2003 (2003-03-13)	1-5, 7, 12, 13, 18-21, 29
Y	page 2, column 2, lines 4-7, 21, paragraph 2; claims 5, 6	6
X	GB 2 155 018 A (STERWIN AG) 18 September 1985 (1985-09-18)  page 2, lines 20, 21, 44-64 page 3, line 3  ----- -/-	1, 2, 7, 8, 12-22, 28-31



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents :

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&amp;\* document member of the same patent family

Date of the actual completion of the international search

23 July 2004

Date of mailing of the international search report

19/10/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2

NL - 2280 HV Rijswijk

Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,

Fax: (+31-70) 340-3016

Authorized officer

Allnutt, S

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB2004/001663

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	SUZUKI GEORGE ET AL: "Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure." CIRCULATION, vol. 106, no. 23, 3 December 2002 (2002-12-03), pages 2967-2972, XP002288136 ISSN: 0009-7322 cited in the application page 2967, column 1, lines 6-8	1-11,29
Y	YAMAKADO M ET AL: "Sites of action of beta-melanocyte stimulating hormone in aldosterone biosynthesis in the rat." PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE. SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE (NEW YORK, N. Y.) JUL 1985, vol. 179, no. 3, July 1985 (1985-07), pages 318-323, XP009033422 ISSN: 0037-9727 see abstract, l. 3-6 page 319, column 2, lines 20-27	1-11,29
Y	ROCHA RICARDO ET AL: "Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart." ENDOCRINOLOGY, vol. 143, no. 12, December 2002 (2002-12), pages 4828-4836, XP002288137 ISSN: 0013-7227 cited in the application page 4828, column 1, lines 14-22 page 4833, column 2, lines 1-33	22,25
Y	ROUSSEAU MICHEL F ET AL: "Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: Results from the RALES neurohormonal substudy." JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 40, no. 9, 6 November 2002 (2002-11-06), pages 1596-1601, XP002288138 ISSN: 0735-1097 page 1599, column 2, lines 1-7 see abstract page 1600, column 1, lines 1-5,20-31	22,25
	----- -/--	

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB2004/001663

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	LEE A F ET AL: "Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study." EUROPEAN JOURNAL OF HEART FAILURE : JOURNAL OF THE WORKING GROUP ON HEART FAILURE OF THE EUROPEAN SOCIETY OF CARDIOLOGY. DEC 1999, vol. 1, no. 4, December 1999 (1999-12), pages 401-406, XP002288261 ISSN: 1388-9842 cited in the application abstract	22-24
A	EP 0 108 606 A (STERWIN AG) 16 May 1984 (1984-05-16) cited in the application page 2, lines 14-20 page 3, lines 1-5 page 5, lines 19-32	13-17

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box II.1

Although claims 29-31 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

-----

## Continuation of Box II.1

Claims Nos.: 1,2,3,7,12-21,29 and 30 (partially)

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

-----

## Continuation of Box II.2

Claims Nos.: 1,2,3,7,12-21,29 and 30 (partially)

Present claim 1 relates to the treatment of a disease which is not well defined. The use of the definition "angiotensin II related disease" in the present context is considered to lead to a lack of clarity within the meaning of Article 6 PCT. It is impossible to determine the diseases for which protection might legitimately be sought. The lack of clarity is such as to render a meaningful complete search impossible. Consequently, the search concerning the therapeutic application of the claimed compounds has been restricted to the diseases listed in claims 4-11.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB2004/001663

## Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1, 2, 3, 7, 12-21, 29 and 30 (partially)  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 29-31 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 1, 2, 3, 7, 12-21, 29 and 30 (partially)  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB2004/001663

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2003050291 A1	13-03-2003	US 2003232798 A1	18-12-2003
GB 2155018 A	18-09-1985	AT 52788 T	15-06-1990
		BE 901813 A1	26-08-1985
		DE 3577710 D1	21-06-1990
		DK 80485 A	26-08-1985
		EP 0154476 A2	17-09-1985
		ES 8706719 A1	16-09-1987
		FI 850759 A	26-08-1985
		GR 850486 A1	26-06-1985
		IT 1184890 B	28-10-1987
		LU 85786 A1	11-12-1985
		NO 850753 A ,B,	26-08-1985
		PT 80008 A ,B	01-03-1985
EP 0108606 A	16-05-1984	AT 38236 T	15-11-1988
		DE 3378318 D1	01-12-1988
		DK 499683 A	03-05-1984
		EP 0108606 A1	16-05-1984
		ES 8504486 A1	16-07-1985
		FI 834025 A	03-05-1984
		GB 2130588 A ,B	06-06-1984
		GR 79688 A1	31-10-1984
		IE 56205 B1	22-05-1991
		JP 1761768 C	28-05-1993
		JP 4043078 B	15-07-1992
		JP 59095300 A	01-06-1984
		NO 833976 A	03-05-1984
		PT 77593 A ,B	01-12-1983